&Partners’s ResMed RMD Stock Holding History

&Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.39M	Buy	27,639 +1,057	+4%	+$219K	0.02%	569
2026 Q1	$5.96M	Buy	26,582 +4,455	+20%	+$1.11M	0.03%	475
2025 Q4	$5.33M	Buy	22,127 +15,710	+245%	+$4.02M	0.03%	470
2025 Q3	$5.37M	Buy	6,417 +513	+9%	+$140K	0.03%	398
2025 Q2	$1.52M	Buy	5,904 +2,503	+74%	+$597K	0.01%	786
2025 Q1	$753K	Buy	3,401 +1,313	+63%	+$307K	0.01%	938
2024 Q4	$484K	Buy	2,088 +1,121	+116%	+$270K	0.01%	1087
2024 Q3	$233K	Buy	+967	New	+$216K	﹤0.01%	1230

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

&Partners's RMD Position: Q2 2026 in Review

&Partners increased its ResMed (RMD) stake by 4% in Q2 2026, buying an estimated $219K and bringing the position to 27,639 shares worth $5.39M. The position accounts for 0.02% of the portfolio, ranked #569.

&Partners first reported a position in RMD in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.96M in Q1 2026. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

&Partners held 27,639 shares of ResMed worth $5.39M as of Q2 2026.
&Partners bought 1,057 ResMed shares in Q2 2026, an estimated $219K.
ResMed made up 0.02% of &Partners's portfolio in Q2 2026, its #569 holding.
&Partners first reported a position in ResMed in Q3 2024 and has held it in 8 quarters since.
&Partners's ResMed position peaked at $5.96M in Q1 2026.
887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.